Table 4 Total discontinuation, dose modification and adverse events related to antiviral treatment
From: HCV genotype 1a shows a better virological response to antiviral therapy than HCV genotype 1b
Subtype 1a n = 165 | Subtype 1b n = 223 | |
|---|---|---|
Total discontinuation n (%) | 18 (11) | 16 (7.1) |
-depression | 7 (4.2) | 3 (1.3) |
-fatigue | 10 (6) | 9 (4) |
-hyperthiroidism | 0 | 1 (0.4) |
-anemia | 1 (0.6) | 3 (1.3) |
Adverse events n (%) | 7 (4.2) | 12 (5.3) |
-depression | 1 (0.6) | 3 (1.3) |
-hypothiroidism | 1 (0.6) | 0 |
-anemia | 5 (3.0) | 7 (3.1) |
-neutropenia | 0 | 2 (0.9) |
Dose modification n (%) | 16 (9.6) | 24 (10.7) |
Peginterferon | 9 (5.4) | 11 (5) |
Ribavirin | 7 (4.2) | 13 (5.8) |